UC Berkeley’s cell therapy developer has filed for an initial public offering.

Caribou Biosciences, a US-based gene therapy developer spun out of University of California (UC) Berkeley, has filed for an initial public offering. Founded in 2011, Caribou is using Crispr genome editing technology to develop modified cell therapies for the treatment of haematologic cancers and solid tumours. It plans to use the IPO proceeds to fund…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.